New Drug Combo Doubles Survival Time for Pancreatic Cancer

A groundbreaking clinical trial shows that adding an antibody called NP137 to standard chemotherapy helped patients with advanced pancreatic cancer live significantly longer.

The treatment worked by blocking a protein that makes tumors resistant to chemotherapy.